Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,347Revenue $M2.9Net Margin (%)-8,293.4Z-Score53.2
Enterprise Value $M3,153EPS $-0.8Operating Margin %-8,823.4F-Score2
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-8,293.4Higher ROA y-yN
Price/Book15.710-y EBITDA Growth Rate %0Quick Ratio12.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio12.7Lower Leverage y-yY
Price/Cash Flow10.0y-y EBITDA Growth Rate %0ROA % (ttm)-25.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-29.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M77.2ROI % (ttm)-12.8Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 43.3768%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 43.3772%New holding200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 43.3782%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 43.3783%Add 23.80%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 43.3783%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 43.3782%New holding209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 43.3782%New holding150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 43.3784%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 43.3785%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 43.3783%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 43.3783%Add 23.00%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 43.3782%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LYONS GARY ADirector 2015-03-24Sell30,000$41.534.43 view
GORMAN KEVIN CHARLESPresident and CEO 2015-03-24Sell40,000$41.534.43 view
Coughlin Timothy PCFO 2015-03-20Sell40,000$44.49-2.52 view
Grigoriadis Dimitri E.Chief Research Officer 2015-02-23Sell20,000$408.43 view
Grigoriadis Dimitri E.Chief Research Officer 2015-02-10Sell20,000$3523.91 view
GORMAN KEVIN CHARLESPresident and CEO 2015-01-16Sell3,750$30.7940.86 view
Grigoriadis Dimitri E.Chief Research Officer 2015-01-16Sell1,625$30.7740.95 view
Bozigian Haig P.Chief Development Officer 2015-01-16Sell1,625$30.7940.86 view
Gano KyleChief Business Dev Officer 2015-01-16Sell1,625$30.840.81 view
Coughlin Timothy PCFO 2015-01-16Sell1,750$30.8140.77 view

Press Releases about NBIX :

    Quarterly/Annual Reports about NBIX:

    News about NBIX:

    Articles On GuruFocus.com
    Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
    5 Strong Healthcare Stocks For 2012 Mar 24 2012 
    Consider These 5 Healthcare Stocks Now Mar 21 2012 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

    More From Other Websites
    Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results Apr 23 2015
    Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results Apr 23 2015
    Market continues to give reason for higher prices Apr 21 2015
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 01 2015
    Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize... Mar 31 2015
    Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize... Mar 31 2015
    Cramer Remix: In all my years, never seen this! Mar 30 2015
    Street Talk: AZPN under the radar Mar 19 2015
    Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast... Mar 10 2015
    Coverage initiated on Neurocrine Biosci by Barclays Mar 04 2015
    Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast... Mar 03 2015
    Neurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Feb 24 2015
    Neurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Feb 24 2015
    Neurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase... Feb 20 2015
    NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 19 2015
    Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock Feb 19 2015
    Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock Feb 19 2015
    Neurocrine Biosciences Announces New Offering Feb 18 2015
    Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock Feb 17 2015
    Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock Feb 17 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK